May 8, 2018 / 12:18 PM / 16 days ago

BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis

May 8 (Reuters) - CymaBay Therapeutics Inc:

* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

* CYMABAY THERAPEUTICS - IT BEGAN SCREENING OF PATIENTS FOR PHASE 2B PROOF OF CONCEPT STUDY OF SELADELPAR FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below